IL254424A0 - Disubstituted heterocyclic tricyclic compounds - Google Patents

Disubstituted heterocyclic tricyclic compounds

Info

Publication number
IL254424A0
IL254424A0 IL254424A IL25442417A IL254424A0 IL 254424 A0 IL254424 A0 IL 254424A0 IL 254424 A IL254424 A IL 254424A IL 25442417 A IL25442417 A IL 25442417A IL 254424 A0 IL254424 A0 IL 254424A0
Authority
IL
Israel
Prior art keywords
heterocyclic compounds
tricyclic heterocyclic
substituted tricyclic
substituted
compounds
Prior art date
Application number
IL254424A
Other languages
English (en)
Hebrew (he)
Inventor
Hai-Yun Xiao
T G Murali Dhar
Jingwu Duan
Bin Jiang
Andrew J Tebben
Original Assignee
Bristol Myers Squibb Co
Xiao Hai Yun
T G Murali Dhar
Jingwu Duan
Bin Jiang
Andrew J Tebben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, Xiao Hai Yun, T G Murali Dhar, Jingwu Duan, Bin Jiang, Andrew J Tebben filed Critical Bristol Myers Squibb Co
Publication of IL254424A0 publication Critical patent/IL254424A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
IL254424A 2015-03-18 2017-09-11 Disubstituted heterocyclic tricyclic compounds IL254424A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562134769P 2015-03-18 2015-03-18
PCT/US2016/022737 WO2016149436A1 (en) 2015-03-18 2016-03-17 Substituted tricyclic heterocyclic compounds

Publications (1)

Publication Number Publication Date
IL254424A0 true IL254424A0 (en) 2017-11-30

Family

ID=55640932

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254424A IL254424A0 (en) 2015-03-18 2017-09-11 Disubstituted heterocyclic tricyclic compounds

Country Status (14)

Country Link
US (1) US10189840B2 (cg-RX-API-DMAC7.html)
EP (1) EP3271360B1 (cg-RX-API-DMAC7.html)
JP (1) JP6793657B2 (cg-RX-API-DMAC7.html)
KR (1) KR102654709B1 (cg-RX-API-DMAC7.html)
CN (1) CN107635993B (cg-RX-API-DMAC7.html)
AU (1) AU2016233288A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017019773A2 (cg-RX-API-DMAC7.html)
CA (1) CA2980159A1 (cg-RX-API-DMAC7.html)
EA (1) EA032315B1 (cg-RX-API-DMAC7.html)
ES (1) ES2797805T3 (cg-RX-API-DMAC7.html)
IL (1) IL254424A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017011434A (cg-RX-API-DMAC7.html)
SG (1) SG11201707469WA (cg-RX-API-DMAC7.html)
WO (1) WO2016149436A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201707473VA (en) 2015-03-18 2017-10-30 Bristol Myers Squibb Co Heterocyclic compounds useful as inhibitors of tnf
MX2017011433A (es) 2015-03-18 2017-11-10 Bristol Myers Squibb Co Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).
UY36630A (es) 2015-04-17 2016-11-30 Abbvie Inc Moduladores tricíclicos de la señalización por tnf
US9879016B2 (en) 2015-04-17 2018-01-30 Abbvie Inc. Indazolones as modulators of TNF signaling
TW201706258A (zh) 2015-04-17 2017-02-16 艾伯維有限公司 作為tnf信號傳遞調節劑之吲唑酮
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
JP6811233B2 (ja) 2015-08-03 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tnfアルファの修飾因子として有用な環状化合物
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
US10953019B2 (en) 2017-03-15 2021-03-23 UCB Biopharma SRL Fused pentacyclic imidazole derivatives as modulators of TNF activity

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6038397B2 (ja) * 1980-03-06 1985-08-31 エスエス製薬株式会社 チアジノイミダゾ−ル誘導体及びその製造法
ATE238998T1 (de) 1997-02-25 2003-05-15 Us Gov Health & Human Serv Substituierte benzimidazole als nicht-nucleoside reverse transcriptase inhibitore
EP1224185B1 (en) * 1999-10-27 2005-11-30 Novartis AG Thiazole and imidazo[4,5-b]pyridine compounds and their pharmaceutical use
US7601846B2 (en) 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
WO2003064422A1 (en) 2002-01-31 2003-08-07 Daiichi Pharmaceutical Co., Ltd. IMIDAZO[1,2-a]PYRIDINE DERIVATIVE
AU2003298839A1 (en) 2002-12-03 2004-06-23 Isis Pharmaceuticals, Inc. Benzimidazoles and analogs thereof as antivirals
US20050124638A1 (en) 2003-12-08 2005-06-09 Swayze Eric E. Benzimidazoles and analogs thereof as antivirals
CN101687865A (zh) * 2007-06-26 2010-03-31 塞诺菲-安万特股份有限公司 稠合的苯并咪唑和氮杂苯并咪唑的区域选择性金属催化合成
FR2919610B1 (fr) * 2007-08-02 2009-10-16 Sanofi Aventis Sa Derives de n-heteroaryl-carboxamides tricycliques,leur preparation et leur application en therapeutique
EP2209785A1 (en) 2007-10-05 2010-07-28 S*BIO Pte Ltd 2-morpholinylpurines as inhibitors of pi3k
JP2009227599A (ja) 2008-03-21 2009-10-08 Daiichi Sankyo Co Ltd イミダゾピリダジン誘導体
CN101717397B (zh) 2008-10-09 2012-11-28 中国科学院上海药物研究所 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物
WO2010080481A1 (en) * 2008-12-19 2010-07-15 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
KR101316982B1 (ko) 2009-03-23 2013-10-15 일라이 릴리 앤드 캄파니 신경계 장애를 검출하기 위한 조영제
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
WO2012148550A1 (en) 2011-02-25 2012-11-01 Myrexis, Inc. Prodrugs of therapeutic compounds
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EA028626B1 (ru) * 2012-06-11 2017-12-29 Юсб Байофарма Спрл БЕНЗИМИДАЗОЛЫ, МОДУЛИРУЮЩИЕ TNF-α
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
GB201321737D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
US9920052B2 (en) 2013-12-09 2018-03-20 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of TNF activity
GB201321743D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321745D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015086523A1 (en) 2013-12-09 2015-06-18 Ucb Biopharma Sprl Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
GB201321746D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321744D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321739D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321735D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321742D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SG11201702759XA (en) 2014-10-06 2017-05-30 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
SG11201707473VA (en) 2015-03-18 2017-10-30 Bristol Myers Squibb Co Heterocyclic compounds useful as inhibitors of tnf
MX2017011433A (es) 2015-03-18 2017-11-10 Bristol Myers Squibb Co Compuestos heterociclicos triciclicos utiles como inhibidores del factor de necrosis tumoral (tnf).

Also Published As

Publication number Publication date
ES2797805T3 (es) 2020-12-03
AU2016233288A1 (en) 2017-11-09
BR112017019773A2 (pt) 2018-05-15
EP3271360B1 (en) 2020-04-22
EP3271360A1 (en) 2018-01-24
JP2018508553A (ja) 2018-03-29
CN107635993B (zh) 2020-05-22
KR20170129810A (ko) 2017-11-27
CA2980159A1 (en) 2016-09-22
US10189840B2 (en) 2019-01-29
WO2016149436A1 (en) 2016-09-22
EA201792034A1 (ru) 2018-03-30
SG11201707469WA (en) 2017-10-30
JP6793657B2 (ja) 2020-12-02
EA032315B1 (ru) 2019-05-31
CN107635993A (zh) 2018-01-26
US20180111936A1 (en) 2018-04-26
KR102654709B1 (ko) 2024-04-03
MX2017011434A (es) 2018-01-25

Similar Documents

Publication Publication Date Title
ZA201807249B (en) Heterocyclic compound
SG11201605417QA (en) Heterocyclic compounds
HUE069702T2 (hu) Heterociklusos vegyület
IL247018A0 (en) Heterocyclic compound
IL248991B (en) Converted dihydroisoquinolinone compounds
IL285105A (en) Heterocyclic compound
IL253361A0 (en) A tricyclic spiro compound
IL254424A0 (en) Disubstituted heterocyclic tricyclic compounds
IL257501B (en) Compounds containing heterocyclic tricyclic compounds
IL262448B (en) Disubstituted heterocyclic bicyclic compounds
HUE049482T2 (hu) Új heterociklusos vegyület
IL254320A0 (en) organic compounds
IL254890A0 (en) The tercyclic compound
IL249907A0 (en) Tricyclic substances containing a triazole ring
GB201521758D0 (en) Organic compounds
GB201501824D0 (en) Organic compounds
IL266099A (en) Heterocyclic composition
HUP1700522A1 (hu) Triciklusos vegyületek